AlgiPharma is attending the 8th International Symposium on Solid Oral Dosage Forms organised by the Swedish Pharmaceutical Society and will take place on 22nd – 25th Sept at the AstraZeneca site in Mölndal, Sweden. Attendees from AlgiPharma will be by our CSO, Dr. Philip Rye, and Dr Ivana Smiljanic our Quality Manager. We are looking […]
AlgiPharma is attending the European Cystic Fibrosis Conference taking place on 4th – 6th June in Milan Italy. Looking forward to catching up with CF colleagues and using the opportunity for further discussions with potential commercial partners. Attendees from AlgiPharma will be our CEO, Yngvar Berg, CSO, Dr. Philip Rye, and Dr Charles Johnson from […]
AlgiPharma presenting at Formulation and Delivery 2024, London, UK We are delighted to have been invited to speak at the Formulation & Delivery 2024 conference, taking place 25th – 26th April in London, UK. AlgiPharma will have two separate presentations highlighting it’s alginate technology for use in the drug delivery of lipid nanoparticles by inhalation […]
R&D Project Manager at AlgiPharma Application Deadline: 28.01.2024 The candidate will proactively manage the day-to-day running of multiple R&D projects, coordinating with key internal and external stakeholders to advance our portfolio of alginate oligosaccharide technologies for drug delivery, drug conjugates and stand-alone API for cystic fibrosis, COPD and infectious diseases. In addition to the basic […]
We are delighted to have been invited to speak at the 2nd Lipid Nanoparticle Development Europe Summit, taking place 17-19th October 2023, in Amsterdam. With lipid nanoparticles (LNPs) moving beyond mRNA vaccines, AlgiPharma is developing its technology to improve the delivery and efficacy of LNP therapeutics. Dr. Philip Rye, Chief Scientific Officer at AlgiPharma will […]
We are extremely pleased to announce the appointment of Preston W. Campbell to the AlgiPharma Board as a non-executive Board Member. His experience and wisdom will be invaluable in guiding the AlgiPharma team and their alginate technology closer to market. Dr. Preston Campbell served at the Cystic Fibrosis Foundation for 25 years where he […]
AlgiPharma attended the LNP Formulation & Process Development conference in Boston, MA (17-19th April). Chief Scientific Officer Dr. Philip Rye presented AlgiPharma’s novel alginate oligosaccharide technology for overcoming inhalation barriers for LNP delivered therapeutics. His presentation highlighted the benefits and challenges associated with the inhalation delivery route, and how AlgiPharma’s technology can mediate the effective […]
We are extremely pleased to announce the appointment of two experienced and high-calibre pharmaceutical experts to the AlgiPharma Board as non-executive Board Members. Their combined expertise will be invaluable in bringing AlgiPharma’s alginate technology closer to market. Dr Charles Johnson is an independent consultant with over 30 years’ experience in the biotechnology industry. He gained […]
AlgiPharma welcomes Mr Ole Tobias Fevang to the AlgiPharma team as accounting manager in support of the Norwegian operations. He has a master’s degree in finance from BI Norwegian Business School. He has previously worked at Norwegian banks (DNB Bank AS and Sparebanken Øst), and more recently four years as an accountant at the international […]
AlgiPharma attends and presents data on its alginate oligosaccharide technology platform at the Lipid Nanoparticles Development Summit 18th-20th October in London. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the […]
